Prolonged Cardiac Monitoring and Stroke Recurrence: A Meta-analysis
Ημερομηνία
2022Γλώσσα
en
Λέξη-κλειδί
Επιτομή
Background and ObjectivesProlonged poststroke cardiac rhythm monitoring (PCM) reveals a substantial proportion of patients with ischemic stroke (IS) with atrial fibrillation (AF) not detected by conventional rhythm monitoring strategies. We evaluated the association between PCM and the institution of stroke preventive strategies and stroke recurrence.MethodsWe searched MEDLINE and SCOPUS databases to identify studies reporting stroke recurrence rates in patients with history of recent IS or TIA receiving PCM compared with patients receiving conventional cardiac rhythm monitoring. Pairwise meta-analyses were performed under the random effects model. To explore for differences between the monitoring strategies, we combined direct and indirect evidence for any given pair of monitoring devices assessed within a randomized controlled trial (RCT).ResultsWe included 8 studies (5 RCTs, 3 observational; 2,994 patients). Patients receiving PCM after their index event had a higher rate of AF detection and anticoagulant initiation in RCTs (risk ratio [RR] 3.91, 95% CI 2.54-6.03; RR 2.16, 95% CI 1.66-2.80, respectively) and observational studies (RR 2.06, 95% CI 1.57-2.70; RR 2.01, 95% CI 1.43-2.83, respectively). PCM was associated with a lower risk of recurrent stroke during follow-up in observational studies (RR 0.29, 95% CI 0.15-0.59), but not in RCTs (RR 0.72, 95% CI 0.49-1.07). In indirect analyses of RCTs, the likelihood of AF detection and anticoagulation initiation was higher for implantable loop recorders compared with Holter monitors and external loop recorders.DiscussionPCM after an IS or TIA can lead to higher rates of AF detection and anticoagulant initiation. There is no solid RCT evidence supporting that PCM may be associated with lower stroke recurrence risk. © American Academy of Neurology.
Collections
Related items
Showing items related by title, author, creator and subject.
-
Surgical and functional outcome of olfactory groove meningiomas: Lessons from the past experience and strategy development
Fountas K.N., Hadjigeorgiou G.F., Kapsalaki E.Z., Paschalis T., Rizea R., Ciurea A.V. (2018)Object: Olfactory groove meningiomas (OGMs) constitute a unique subset of intracranial meningiomas, since they usually remain clinically silent for a long period of time, and they may be of large size upon their diagnosis. ... -
Risk Stratification for Recurrence and Mortality in Embolic Stroke of Undetermined Source
Ntaios G., Vemmos K., Lip G.Y.H., Koroboki E., Manios E., Vemmou A., Rodríguez-Campello A., Cuadrado-Godia E., Giralt-Steinhauer E., Arnao V., Caso V., Paciaroni M., Diez-Tejedor E., Fuentes B., Pérez Lucas J., Arauz A., Ameriso S.F., Hawkes M.A., Pertierra L., Gómez-Schneider M., Bandini F., Chavarria Cano B., Iglesias Mohedano A.M., García Pastor A., Gil-Núñez A., Putaala J., Tatlisumak T., Barboza M.A., Athanasakis G., Makaritsis K., Papavasileiou V. (2016)Background and Purpose - The risk of stroke recurrence in patients with Embolic Stroke of Undetermined Source (ESUS) is high, and the optimal antithrombotic strategy for secondary prevention is unclear. We investigated ... -
Real-world data on Len/Dex combination at second-line therapy of multiple myeloma: treatment at biochemical relapse is a significant prognostic factor for progression-free survival
Katodritou E., Kyrtsonis M.-C., Delimpasi S., Kyriakou D., Symeonidis A., Spanoudakis E., Vasilopoulos G., Anagnostopoulos A., Kioumi A., Zikos P., Aktypi A., Briasoulis E., Megalakaki A., Repousis P., Adamopoulos I., Gogos D., Kotsopoulou M., Pappa V., Papadaki E., Fotiou D., Nikolaou E., Giannopoulou E., Hatzimichael E., Giannakoulas N., Douka V., Kokoviadou K., Timotheatou D., Terpos E. (2018)We evaluated progression-free survival (PFS) rate of patients treated with lenalidomide/dexamethasone (Len/Dex), the efficacy of the combination, and the prognostic significance of treatment at biochemical vs. clinical ...